Clinical Course of 195 Critically Ill COVID-19 Patients: A Retrospective Multicenter Study

Shock. 2020 Nov;54(5):644-651. doi: 10.1097/SHK.0000000000001629.

Abstract

Introduction: Coronavirus disease-2019 (COVID-19) outbreak has spread around the world. However, the dynamic course of critically ill COVID-19 has not been described thoroughly.

Patients and methods: We retrospectively analyzed 195 critically ill COVID-19 patients in Hubei province, China, between January 5, 2020 and April 3, 2020. Epidemiologic data, clinical features, treatments, and outcomes were collected and analyzed.

Results: Most critically ill patients were older with higher Acute Physiology and Chronic Health Evaluation II scores. After critical illness onset, a total of 181 (92.8%) patients received ventilation support, of which 84 (43.1%) received noninvasive and 97 (49.7%) received invasive mechanic ventilation (IMV). Among the 97 patients with IMV, 28 (28.9%) received prone ventilation, 57 (58.8%) received neuromuscular blocked therapy, and 22 (11.3%) received tracheostomy due to prolonged ventilator use. Early hypoxemia, subsequent hypercapnia, pulmonary hypertension, and finally pulmonary fibrosis were notable in the clinical course of acute respiratory distress syndrome (ARDS). Eighty-nine (45.6%) patients presented with shock. Acute kidney injury (29.7%) and secondary infection (28.2%) were also notable. The overall mortality of critically ill patients at day 28 was 42.1%. Intensive care unit (ICU) mortality was around 33%, as 16 patients died prior to ICU admission. A low PaO2/FiO2 ratio was an independent risk factor for death. High viral load was observed in most non-survivors.

Conclusion: ARDS and shock were notable in the critical illness of COVID-19. Ventilation support and hemodynamic support were the cornerstones for critical care. High viral load was associated with death of critically ill COVID-19 patients.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • COVID-19
  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / therapeutic use*
  • China / epidemiology
  • Coronavirus Infections / complications
  • Coronavirus Infections / mortality
  • Coronavirus Infections / physiopathology
  • Coronavirus Infections / therapy*
  • Critical Illness
  • Disease Progression
  • Female
  • Hemodynamics / drug effects*
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / physiopathology
  • Pneumonia, Viral / therapy*
  • Respiration, Artificial* / adverse effects
  • Respiration, Artificial* / mortality
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • Treatment Outcome
  • Viral Load

Substances

  • Cardiovascular Agents